ライフサイエンスコーパス: subcutaneous

1 nally, Y-27632 treatment inhibited growth of subcutaneous 786-OT1 CC-RCC tumors in mice.

2 y into separate cohorts of nude mice bearing subcutaneous A-431 tumors.

3 ogical actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF),

4 ver (ACADM) and insulin signalling (IRS2) in subcutaneous abdominal adipose tissue.

5 ith no association seen between DeltaLAV and subcutaneous abdominal fat (P=0.47) or lower body fat (P

6 stricted environment of the host, such as in subcutaneous abscesses.

7 nib (5 mg twice daily) plus methotrexate, or subcutaneous adalimumab (40 mg every other week) plus me

8 The smaller subcutaneous adipocyte size predicted better glycemic co

9 for the use of SGBS vis-a-vis primary human subcutaneous adipocytes as a human white adipocyte model

10 nhibits flow-induced vasodilatation in human subcutaneous adipose microvessels.

11 mmation, elevated adiponectin, mulitilocular subcutaneous adipose tissue (inguinal WAT) with upregula

12 effect of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) area on metabolic synd

13 VAT and subcutaneous adipose tissue (SAT) samples obtained from

14 Abdominal subcutaneous adipose tissue biopsy samples were collecte

15 exhibited coincident eQTLs (P < 1 x 10-5) in subcutaneous adipose tissue for BPTF and PDGFC.

16 ups receiving high perinatal n-6/n-3 ratios, subcutaneous adipose tissue in 14-day-old wild-type pups

17 ait locus (eQTL) analyses by using abdominal subcutaneous adipose tissue of 770 extensively phenotype

18 insulin sensitivity, and losing superficial subcutaneous adipose tissue remained neutral except for

19 Subcutaneous adipose tissue samples were collected and a

20 Subcutaneous adipose tissue stores excess lipids and mai

21 ted with improved lipid profile, losing deep subcutaneous adipose tissue with improved insulin sensit

22 zed by a thin superficial layer of abdominal subcutaneous adipose tissue, increased visceral adipose

23 tiated preadipocytes in both human and mouse subcutaneous adipose tissues.

24 munoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treat

25 Subcutaneous administration does not compromise the anti

26 Subcutaneous administration of ALN-GO1 resulted in poten

27 een, and liver) under Cu deficiency and that subcutaneous administration of Cu to these animals resto

28 Subcutaneous administration of NRTN to 8-week-old male Z

29 IgE-omalizumab complexes were observed after subcutaneous administration of omalizumab.

30 HCV genotypes 1, 3, and 4 received a single subcutaneous administration of RG-101 at 2 mg/kg (n = 14

31 The subcutaneous administration of the nanofibrils in rats r

32 Upon subcutaneous administration, C10OOc12O exhibited high ci

33 ografts in NOD/SCID-gamma mice after oral or subcutaneous administration; D538G tumors were more pote

34 oxide in cells and ex vivo using mice with a subcutaneous air pouch as a model for inflammation.

35 ousness of the biosensor performance towards subcutaneous alcohol monitoring was substantiated by the

36 mally invasive electrochemical monitoring of subcutaneous alcohol.

37 Most of the SRs occurred in subcutaneous allergen immunotherapy (SCIT) (89%, n = 97)

38 A novel subcutaneous allergen immunotherapy formulation (gpASIT+

39 years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be

40 To evaluate the effect of subcutaneous anakinra versus placebo on fatigue severity

41 Participants were randomly assigned to daily subcutaneous anakinra, 100 mg (n = 25), or placebo (n =

42 distribution) of the same materials in mouse subcutaneous and dog tibia implant models, we demonstrat

43 ivity, chemoresistance, and tumorigenesis in subcutaneous and intrabursal mouse xenograft models of h

44 rapies for hepatoblastoma (HB) is limited to subcutaneous and intrasplenic xenograft models that do n

45 motive behavioral changes following repeated subcutaneous and intravenous heroin challenges in mice a

46 he tissue mimics matched expected values for subcutaneous and muscle tissue, and that the compliance

47 labeled SC16 antibody enabled delineation of subcutaneous and orthotopic SCLC tumor xenografts as wel

48 re-clinical data help prove the concept that subcutaneous and subconjunctival injection of HC-HA/PTX3

49 Current data support the effectiveness of subcutaneous and sublingual immunotherapy in rhinitis.

50 patic proton-density fat fraction [PDFF] and subcutaneous and visceral abdominal fat).

51 Adipocyte numbers were decreased in both subcutaneous and visceral adipose tissue of TRPC1 KO mic

52 ression and increased Wnt expression in both subcutaneous and visceral adipose tissues and impaired a

53 macokinetics shows that both intravenous and subcutaneous applications are viable routes for the deli

54 expression of UCP1 and beige adipogenesis of subcutaneous AT in obesity.

55 In mice, subcutaneous AT Tshb expression levels correlated direct

56 Intratumoral administration of ISF35 in subcutaneous B16 melanomas generates tumor-specific, CD8

57 ma were randomly assigned (1:1:1) to receive subcutaneous benralizumab 30 mg, either every 4 weeks or

58 Upon subcutaneous biomaterial implantation, Sox10(+) stem cel

59 To evaluate the ability of a novel, weekly, subcutaneous buprenorphine depot formulation, CAM2038, t

60 ditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor twice weekly significantly red

61 nts were randomly assigned to receive single subcutaneous canakinumab 150 mg or placebo injections fo

62 Cancer cells, mice with subcutaneous cancer esophageal xenografts, and nude rats

63 nary challenge but, interestingly, not after subcutaneous challenge.

64 enerally succumbing within 5 to 6 days after subcutaneous challenge.

65 mic (18)F-FDG measurement of a mouse bearing subcutaneous colon cancer and validated using histology.

66 hieved by administering the antagonists as a subcutaneous continuous infusion for 2 weeks compared to

67 the efficacy and safety of self-administered subcutaneous CSL830 in patients with type I or type II h

68 nner - low systemic Cu increases ATP7A while subcutaneous Cu administration decreases ATP7A suggestin

69 dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram

70 Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite ou

71 from a continuous glucose monitor to control subcutaneous delivery of insulin and glucagon.

72 model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue w

73 ere randomly assigned (1:1) to receive 60 mg subcutaneous denosumab or placebo every 6 months for 3 y

74 ed under the kidney capsule (KC) or into the subcutaneous deviceless (DL) site at a marginal islet do

75 All other skin and subcutaneous diseases composed 0.12% of total DALYs.

76 Skin and subcutaneous diseases were the 18th leading cause of glo

77 HIV-positive men were randomised to a single subcutaneous dose of C34-PEG4-Chol at incrementing doses

78 to TGF-beta1 mAb (2-, 10-, or 50-mg monthly subcutaneous dosing for 12 months) or placebo.

79 Patients were randomly assigned (3:1:3) to subcutaneous dupilumab 300 mg once weekly (qw), dupiluma

80 We implanted subcutaneous electrocardiographic monitors (St. Jude CON

81 patoblasts, but were readily expressed after subcutaneous engraftment and tumor growth.

82 once daily for 35-42 days) or standard-dose subcutaneous enoxaparin (40 mg once daily for 10+/-4 day

83 he effects of atorvastatin (80 mg daily) and subcutaneous evolocumab (420 mg every 2 weeks) for 8 wee

84 her amount of total body fat (p < 0.001) and subcutaneous fat (p < 0.001) than those without NAFLD.

85 d by a layered closure of the ischioanal and subcutaneous fat and skin similar to the control interve

86 gene, PLIN2, expressed only by sebocytes and subcutaneous fat cells.

87 ed waist circumference (11-13 cm), abdominal subcutaneous fat mass (1650-1850 cm(3)), visceral fat ma

88 Subcutaneous fat mass was not associated with any respir

89 The abdominal fat area (AFA) and subcutaneous fat thickness (SFT) were measured using T1-

90 Liver fat, VAT, and subcutaneous fat were determined by magnetic resonance s

91 ction on DNL, liver fat, visceral fat (VAT), subcutaneous fat, and insulin kinetics in obese Latino a

92 circulating, free base form of the drug into subcutaneous fat.

93 he connection between the nervous system and subcutaneous fat.

94 e significantly more likely to have required subcutaneous fluid administration.

95 to receive 10 mg oral rivaroxaban or 2.5 mg subcutaneous fondaparinux once a day for 45 days.

96 A subcutaneous formulation could reduce patients' treatmen

97 Metastasis from subcutaneous fs120 tumors was more sensitive than fs188

98 Accurate identification of the agents of subcutaneous fungal infection is essential to guide appr

99 eive standard care (control), treatment with subcutaneous G-CSF (lenograstim) 15 mug/kg for 5 days, o

100 le being well tolerated by nude mice bearing subcutaneous GPA33-positive SW1222 xenografts.

101 travenous group and 95 (48%) patients in the subcutaneous group (mainly grade 1 or 2 local injection-

102 intravenous group vs 189 [96%] of 197 in the subcutaneous group); the frequency of adverse events of

103 in the intravenous group and 52 (26%) in the subcutaneous group.

104 travenous group and 84.4% (78.7-89.1) in the subcutaneous group.

105 in the intravenous group and 73 (37%) in the subcutaneous group.

106 s (butter fat, subcutaneous pig back-fat and subcutaneous ham fat).

107 PBAE NP administration to a subcutaneous HCC mouse model, established with one of th

108 ke was studied in nude BALB/c mice bearing a subcutaneous HER3 overexpressing H441 non-small cell lun

109 infused into immunocompromised mice bearing subcutaneous human U87 glioblastomas expressing EGFRvIII

110 randomized within 6 hours of presentation to subcutaneous icatibant 30 mg or placebo at 0 and 6 hours

111 Patients received either subcutaneous IFN-alpha2a, systemic corticosteroids, or n

112 Only subcutaneous immunization with Alum-adsorbed rBet v 1 an

113 Subcutaneous immunization with neoglycoconjugate protect

114 Subcutaneous immunization with shR-SOCS1-transduced viab

115 Subcutaneous immunoglobulin (SCIg) is an alternative opt

116 ponse in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated th

117 and monthly placebo injections), 36 received subcutaneous immunotherapy (monthly injections containin

118 nical efficacy and safety of Phleum pratense subcutaneous immunotherapy (Phl-SCIT) in LAR.

119 Subcutaneous immunotherapy (SCIT) had a short-term and s

120 elivery of Ova using the clinically-approved subcutaneous immunotherapy (SCIT) route.

121 ted that sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) would be considered co

122 r by comparing with other therapies, such as subcutaneous immunotherapy (SCIT), or other pharmacother

123 gic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatmen

124 Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy

125 Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal all

126 Subcutaneous immunotherapy was included as a positive co

127 red to compare sublingual immunotherapy with subcutaneous immunotherapy.

128 ro-regenerative environment at the site of a subcutaneous implant.

129 iomyopathy (HCM) ECG make it a challenge for subcutaneous implantable cardioverter-defibrillator (S-I

130 The subcutaneous implantable cardioverter-defibrillator (S-I

131 aluate 4 different implant techniques of the subcutaneous implantable cardioverter-defibrillator.

132 METHODS AND Patients implanted with subcutaneous implantable cardioverter-defibrillators fro

133 Tissue responses were studied in vivo after subcutaneous implantation in rats.

134 om lung and breast cancer) were developed by subcutaneous implantation of patient tumor fragments.

135 ible alternatives to the standard 3-incision subcutaneous implantation, and the 2-incision technique

136 Ca cells led to ectopic bone formation under subcutaneous implantation.

137 All infections occurred in subcutaneous implants (3-incision, n=3; 2-incision, n=4)

138 nce levels of the steroid were controlled by subcutaneous implants, thus suggesting actions related t

139 he pneumonia model but high virulence in the subcutaneous infection model, suggesting that the virule

140 rophil recruitment and systemic infection in subcutaneous infection of mice by MGAS315, a hypervirule

141 of neutrophil recruitment, and virulence in subcutaneous infection of mice.

142 anscription at stationary growth phase or in subcutaneous infection of mice.

143 Thus, GAS RocA mutants can be selected in subcutaneous infections in mice and exhibit gene express

144 The remaining two isolates, both from subcutaneous infections, are distantly related to Exophi

145 and Parathyridaria percutanea cause similar subcutaneous infections, but these infections lack the d

146 murine cardiac injury model was performed by subcutaneous infusion of either saline or Angiotensin II

147 Mice received monthly subcutaneous infusions of cytokines while also being ass

148 f fatty acid-binding protein 4 and increased subcutaneous inguinal adipose tissue expression of adipo

149 However, in subcutaneous inguinal fat (iWAT), rosiglitazone markedly

150 Transcriptomic analysis of subcutaneous inguinal white adipose tissue in the absenc

151 that beige adipocytes formed postnatally in subcutaneous inguinal white adipose tissue lost thermoge

152 the proximal region of the Ucp1 promoter in subcutaneous inguinal white adipose tissue.

153 significant difference (p>0.05) compared to subcutaneous injection (24+/-13min).

154 ndaparinux because it does not require daily subcutaneous injection and is cheaper.

155 e limitations of current DHE formulations in subcutaneous injection and nasal spray such as pain, adv

156 r 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in pat

157 6h in chemical-induced diabetes mice, while subcutaneous injection failed to maintain blood glucose

158 g-dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for card

159 The first cohort received one subcutaneous injection of 2 mg/kg RG-101 or placebo; the

160 1 or placebo; the second cohort received one subcutaneous injection of 4 mg/kg or placebo.

161 enerated randomisation schedule to receive a subcutaneous injection of 7.5 mg, 22.5 mg, 75 mg, or 225

162 eceiving an anti-myostatin PINTA745 (n = 12; subcutaneous injection of 7.5 mg.kg(-1) PINTA745 immedia

163 puter-generated random sequence to receive a subcutaneous injection of 80 mg ixekizumab every 4 weeks

164 assessed by comparison with intradermal and subcutaneous injection of antigen using a 27G needle and

165 We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of

166 d participants (1:1) by country to receive a subcutaneous injection of either mepolizumab 100 mg or p

167 r results indicated that subconjunctival and subcutaneous injection of HC-HA/PTX3 preserved tear secr

168 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in eithe

169 Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or placebo.

170 synaptosomes, and in striatum of rats given subcutaneous injection of METH.

171 Furthermore, subcutaneous injection of recombinant TWEAK into naive m

172 e performed on tumor-bearing nude mice after subcutaneous injection of RIN-m5F cells.

173 g/m(2)) was given as an intravenous bolus or subcutaneous injection on days 1, 4, 8, and 11 of 21-day

174 local skin inflammatory reaction limited to subcutaneous injection site and elicited no other toxic

175 nergy expenditure in mice was measured after subcutaneous injection with vehicle, 1 mg norepinephrine

176 t hardly penetrated into the lungs following subcutaneous injection, as opposed to pulmonary delivery

177 1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of

178 nificantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability

179 treatment option instead of a more expensive subcutaneous injection.

180 ab and placebo were administered by means of subcutaneous injection.

181 Subcutaneous injections and the sublingual route have be

182 scid)Il2rg(tm1Wjl)/SzJ (NSG) mice were given subcutaneous injections of AMC-EAC-007B cells and also g

183 After repeated subcutaneous injections of anti-mLAMalpha3 IgG erosions

184 ease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo onc

185 previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at

186 EAE mice were given subcutaneous injections of myelin oligodendrocyte glycop

187 ose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligo

188 assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg

189 Animals received subcutaneous injections of saline or liraglutide (0.005-

190 bution and PET studies after intravenous and subcutaneous injections showed similar patterns and kine

191 All patients received weekly subcutaneous injections, with the active treatment group

192 tment through both intravenous and non-local subcutaneous injections.

193 ks or 420 mg monthly) or matching placebo as subcutaneous injections.

194 t meal-time insulin boluses) or conventional subcutaneous insulin delivery according to local clinica

195 multiple daily injections (MDI), continuous subcutaneous insulin infusion (CSII) and islet transplan

196 uous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be used to improve the

197 itiation of insulin pump therapy (continuous subcutaneous insulin infusion; CSII) in patients with ty

198 is safe and effective compared with standard subcutaneous insulin therapy in patients with type 2 dia

199 of early versus delayed treatment (DT) with subcutaneous interferon (sc IFN) beta-1a 44 mug in patie

200 izumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mug thre

201 We report that the efficiency of subcutaneous islet transplantation in a Lewis rat model

202 mising approach to successfully establishing subcutaneous islet transplantation.

203 dines was reflected in lipid accumulation in subcutaneous layer and visceral fat and not in the liver

204 From superficial to deep, there is the subcutaneous layer, which regulates orifice closure, the

205 mechanical properties of skin or that of the subcutaneous layers.

206 A biopsy of the subcutaneous lesion showed histological and immunohistoc

207 n schedule with no stratification to receive subcutaneous liraglutide (3.0 mg) or placebo, with stand

208 telephone or web-based system, to once-daily subcutaneous liraglutide 3.0 mg or matched placebo, as a

209 f different fat depots (deep and superficial subcutaneous, liver, pericardial, muscle, pancreas, and

210 ere randomized to receive adalimumab, 80-mg, subcutaneous loading dose followed by 40 mg every other

211 m cells were found sparsely in the stroma of subcutaneous loose connective tissues.

212 Similarly, in the subcutaneous Matrigel plug assay, which mimics ischemic/

213 n wounds and reduced angiogenic sprouting in subcutaneous matrigel plugs.

214 on-Hodgkin lymphoma and a B16 mouse model of subcutaneous melanoma are used to extract a snapshot of

215 effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to s

216 a favourable 52 week risk-benefit profile of subcutaneous methotrexate in patients with psoriasis.

217 Subcutaneous methotrexate was generally well tolerated;

218 Treatment with exendin-4 (Ex-4) delivered by subcutaneous micro-osmotic pumps 48 hours prior to or 2

219 Kir channels also contribute to FIV in human subcutaneous microvessels.

220 uscle tissue, and that the compliance of the subcutaneous mimics increased linearly with water conten

221 ul alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain

222 Although transplantation of cardiac MSCs and subcutaneous MSCs from LVD and sham hearts did not impro

223 D on MSCs, we characterized cardiac MSCs and subcutaneous MSCs in vitro.

224 The effect of LVD on subcutaneous MSCs was less remarkable.

225 radermal injection using the jet injector or subcutaneous needle injection exhibited comparable immun

226 omly assigned participants (1:1:1) to either subcutaneous once-weekly 0.5 mg or 1.0 mg semaglutide (d

227 ons (TcPAbs) can protect mice against lethal subcutaneous or aerosol challenge with VEEV.

228 In human xenograft models of subcutaneous or orthotopic HCC, administration of the se

229 imilar safety profile to that of twice-daily subcutaneous pasireotide.

230 ecies from confirmed cases of eumycetoma and subcutaneous pedal masses, previously formally identifie

231 with 250 mg intravenous REP 2139 and 180 mug subcutaneous pegylated interferon alfa-2a once per week

232 ween SGBS adipocytes and primary human white subcutaneous (PHWSC) adipocytes.

233 was investigated in animal fats (butter fat, subcutaneous pig back-fat and subcutaneous ham fat).

234 e web-based voice response system to receive subcutaneous placebo or benralizumab 30 mg injections ev

235 Patients were randomly assigned (3:2:2) to subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg

236 ADCs were performed on BALB/c nude mice with subcutaneous PSMA-positive LS174T-PSMA xenografts.

237 of an LV endocardial pacing electrode and a subcutaneous pulse generator.

238 Finally, animals with subcutaneous R3230 adenocarcinoma tumors were allocated

239 INTERPRETATION: Intravenous and subcutaneous rituximab had similar efficacy and safety p

240 show the pharmacokinetic non-inferiority of subcutaneous rituximab to intravenous rituximab in folli

241 375 mg/m(2) intravenous rituximab or 1400 mg subcutaneous rituximab, plus chemotherapy (six-to-eight

242 ned, 205 to intravenous rituximab and 205 to subcutaneous rituximab.

243 interactive voice response system to receive subcutaneous romosozumab (210 mg once monthly) or subcut

244 igned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendro

245 he intramuscular route is preferred over the subcutaneous route for vaccine administration and that t

246 e nasal viral load when administered via the subcutaneous route.

247 l relationship between intramuscular (IM) or subcutaneous (SC) drug depot morphology and distribution

248 A single subcutaneous (SC) injection of plerixafor results in rap

249 (PKs) of methylone and its metabolites after subcutaneous (sc) methylone administration (3, 6, 12 mg/

250 We found that subcutaneous (SC) OA-NO2 injections administered 18 h pr

251 atment group 1 [T1], n = 20); eleven 5 mg/kg subcutaneous (SC) VRC01 (treatment group 3 [T3], n = 20)

252 Human subcutaneous (SC) white adipose tissue (WAT) increases t

253 (dosage-dependent range, -0.7% to -1.9%) and subcutaneous semaglutide (-1.9%) and placebo (-0.3%); or

254 age-dependent range, -2.1 kg to -6.9 kg) and subcutaneous semaglutide (-6.4 kg) vs placebo (-1.2 kg),

255 lutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control

256 lacebo (n = 71; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks

257 ional intrahepatic transplantation site, the subcutaneous site requires a large number of islets to a

258 ains viability and function of islets in the subcutaneous site.

259 ftment most effectively in the portal and DL subcutaneous sites.

260 We used oxygen recordings in the subcutaneous space to confirm that fentanyl-induced brai

261 e web response system (stratified by age) to subcutaneous TDV injection (one 0.5 mL dose containing 2

262 taneous romosozumab (210 mg once monthly) or subcutaneous teriparatide (20 mug once daily).

263 blind, placebo-controlled trial, we compared subcutaneous tezepelumab at three dose levels with place

264 ith semaglutide, and others such as skin and subcutaneous tissue disorders (eg, rash, pruritus, and u

265 verse events (AEs) included nausea, skin and subcutaneous tissue disorders (SSTD), diarrhea, and fati

266 Subcutaneous tissue is a promising site for islet transp

267 odular lesions in the ears and a lump in the subcutaneous tissue of the left arm.

268 These data demonstrate the importance of subcutaneous tissue on microneedle performance and the n

269 ontent (67, 80, 88 and 96%) to represent the subcutaneous tissue, and a type of ballistic gelatine, P

270 ed multiple hypermetabolic lesions involving subcutaneous tissue, muscle osseous structures, and bone

271 251 patients, in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or

272 ls may participate in bone angiogenesis upon subcutaneous transplantation in a nude mouse.

273 B20-4.1.1 inhibited subcutaneous tumor growth and decreased vascular density

274 cogenic and transforms melanocytes, enabling subcutaneous tumor growth in vivo.

275 lly, exogenous expression of JMJD2B enhanced subcutaneous tumor growth of colon cancer cells in a p53

276 tastatic colonies in lungs without affecting subcutaneous tumor growth.

277 ted regimen of alpha-radioimmunotherapy in a subcutaneous tumor model in mice.

278 Mice bearing subcutaneous tumors (50 mm(3), NIH:OVCAR-3) were injecte

279 D scid gamma-(NSG) mice were inoculated with subcutaneous tumors engineered to either be constitutive

280 ngle cell level and in connecting tissues of subcutaneous tumors in mice.

281 These subcutaneous tumors were metastatic to regional lymph no

282 ced durable and complete remissions of large subcutaneous tumors without detectable side effects.

283 alphavbeta6 negative (A375Ppuro and PANC-1) subcutaneous tumour mouse models.

284 Mammary or subcutaneous tumours grow despite suppression of NFS1, w

285 or drug discovery are based on orthotopic or subcutaneous tumours.

286 Subcutaneous ustekinumab, 45 mg, at weeks 0 and 4 and qu

287 ctivated early (2 hours) in both BAT and the subcutaneous WAT depots, with the most striking change b

288 have highlighted differences in visceral and subcutaneous WAT thermogenic metabolism and demonstrate

289 s reduces blood flow and (18)F-FDG uptake in subcutaneous WAT, indicating that the physiologic respon

290 Unlike subcutaneous WAT, visceral WAT is resistant to adopting

291 of thermogenic genes (Ucp1 and Ppargc1a) in subcutaneous WAT.

292 e expression and mitochondrial biogenesis in subcutaneous WAT.

293 ith alemtuzumab induction (15-30 mg, 1 dose, subcutaneous), whereas 35 nonsensitized patients receive

294 Subcutaneous white adipose tissue (scWAT) is the major f

295 in obesity whereas preferential expansion of subcutaneous white adipose tissue (WAT) appears protecti

296 Browning of subcutaneous white fat (iWAT) involves several reprogram

297 pyrvinium pamoate is further confirmed in a subcutaneous xenograft model.

298 showed that the knockdown of LAMB1 or K19 in subcutaneous xenograft mouse models resulted in signific

299 e to compounds in culture, and when grown as subcutaneous xenograft tumors in mice.

300 dozens of cancer cell lines in vitro and on subcutaneous xenograft tumors in mice.